PF-AtlasКлинические испытания › NCT06573164

Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis

Bacillus clausii tablets(Qipian®) · Не указано

ID реестра
NCT06573164
Фаза
Не указано
Статус
Завершено
Препарат / вмешательство
Bacillus clausii tablets(Qipian®)
Спонсор
Second Affiliated Hospital, School of Medicine, Zhejiang University
Начало
2024-01-01
Набор участников
60
Центры
1

Об исследовании

Allergic rhinitis and asthma are common respiratory diseases. Qipian® is a Chinese medicine made from three types of bacteria, used to treat these conditions. This study will retrospectively analyze the effects of adding Qipian® to the regular treatment for patients with allergic rhinitis, with or without asthma. Patients meeting the Allergic Rhinitis and its Impact on Asthma(ARIA) and Global Initiative for Asthma(GINA) diagnostic criteria were divided into two groups: one receiving standard drug treatment, and the other receiving standard treatment plus Qipian®. The study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding Qipian® leads to better outcomes than the standard treatment alone.This study aims to determine how Qipian® benefits patients with rhinitis and asthma and its effect on related serum indicators, helping to explore its role in allergic respiratory diseases.

Открыть NCT06573164 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT06573164 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.